#夏季日常随手拍#
The iteration of the large infusion is carried out from two paths at the same time: first, the packaging form; Second, clinical use.
The technical iteration of the packaging form has passed: open infusion system (first generation→), semi-open infusion system (second generation), → fully closed infusion system (third generation).
The first generation material is glass, the second generation material is plastic, and the third material is non-PVC and plastic
The technical iteration of clinical use is the following chain:
Basic infusion (glucose infusion, sodium chloride infusion, etc.), → infusion for blood volume expansion (dextran infusion, hydroxyethyl starch infusion, etc.), → dialysis infusion (gastrozoar, iohexol injection, etc.), → therapeutic infusion (tinidazole infusion, ofloxacin infusion, etc.), → nutritional infusion (amino acid infusion, fat emulsion infusion, carbohydrate infusion, etc.)
For a long time, the change of packaging form was invented by a U.S. stock company, which is called: Baxter International (BAX)
Although intravenous administration can quickly reach the whole body through blood circulation, it is also suitable for buying precious time when rescuing patients. However, doctors in United States will not give infusions to patients casually, first, to avoid patients from developing drug resistance; second, because the infusion is more prone to adverse reactions; third, cross-infection will occur; Fourth, it is to reduce the pain of patients when taking drugs.
The first of these is the one that doctors consider the most.
Because, the United States large infusion companies mostly focus on the field of high value-added treatment and nutritional infusion.
For example, Baxter has laid out the fields of hemodialysis and kidney dialysis, while its competitor Fresenius has laid out the fields of blood products and anesthetics.
But in China, the environment for large infusions is completely different, and it can be said that it is quite low-end.
At this stage, the materials of large infusions are still dominated by low-end glass bottles and plastic bottles, accounting for 40% of the market share, while high-end non-PVC soft bags and upright soft bag products account for only 20% in total
In addition, from the perspective of drug structure, it is also relatively "backward", mostly based on low-end large infusions such as basic large infusions and antibiotics, and there are few high-end large infusion products
At present, Shisi Pharmaceutical ranks among the top three in the large infusion industry, with a market share of 12%, second only to Kelun Pharmaceutical (41%) and China Resources Shuanghe (14%)
Shi Siyao is obviously only the third in the industry, why do you let the industry leader Kelun Pharmaceutical ignore it, but study the third?
Predict the follow-up and listen to the next breakdown
It does not constitute any investment advice, the stock market is risky, and you need to be cautious when entering the market